Amarin (AMRN) Competitors $15.38 +0.22 (+1.45%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$15.38 0.00 (-0.01%) As of 08/4/2025 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. CDTX, NTLA, HROW, CVAC, CALT, PHVS, PAHC, AVDL, ARDX, and PRAXShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Cidara Therapeutics (CDTX), Intellia Therapeutics (NTLA), Harrow (HROW), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Pharvaris (PHVS), Phibro Animal Health (PAHC), Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Its Competitors Cidara Therapeutics Intellia Therapeutics Harrow CureVac Calliditas Therapeutics AB (publ) Pharvaris Phibro Animal Health Avadel Pharmaceuticals Ardelyx Praxis Precision Medicines Amarin (NASDAQ:AMRN) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment. Which has stronger valuation & earnings, AMRN or CDTX? Amarin has higher revenue and earnings than Cidara Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M1.39-$82.18M-$3.67-4.19Cidara Therapeutics$1.27M991.49-$169.83M-$29.47-2.12 Is AMRN or CDTX more profitable? Cidara Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -47.22%. Amarin's return on equity of -21.18% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amarin-47.22% -21.18% -15.00% Cidara Therapeutics N/A -73.04%-54.28% Does the media favor AMRN or CDTX? In the previous week, Amarin had 12 more articles in the media than Cidara Therapeutics. MarketBeat recorded 13 mentions for Amarin and 1 mentions for Cidara Therapeutics. Amarin's average media sentiment score of 0.11 beat Cidara Therapeutics' score of 0.00 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cidara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals hold more shares of AMRN or CDTX? 22.3% of Amarin shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 2.0% of Amarin shares are owned by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, AMRN or CDTX? Amarin has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Do analysts rate AMRN or CDTX? Amarin presently has a consensus target price of $12.00, suggesting a potential downside of 21.98%. Cidara Therapeutics has a consensus target price of $57.29, suggesting a potential downside of 8.28%. Given Cidara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cidara Therapeutics is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryCidara Therapeutics beats Amarin on 10 of the 17 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$313.92M$3.02B$5.51B$9.35BDividend YieldN/A2.46%4.74%4.15%P/E Ratio-4.1918.0629.1424.41Price / Sales1.39272.86435.05101.09Price / CashN/A40.5624.4827.20Price / Book0.658.628.525.77Net Income-$82.18M-$54.98M$3.24B$264.99M7 Day Performance4.98%-0.87%0.65%-0.68%1 Month Performance-5.03%16.08%7.97%7.08%1 Year Performance17.60%14.18%30.98%23.80% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.562 of 5 stars$15.38+1.5%$12.00-22.0%+20.2%$313.92M$228.61M-4.19360Earnings ReportAnalyst UpgradeCDTXCidara Therapeutics2.9032 of 5 stars$62.46-0.7%$57.29-8.3%+425.8%$1.26B$1.27M-2.1290Upcoming EarningsNTLAIntellia Therapeutics4.5838 of 5 stars$12.12+5.5%$33.37+175.3%-49.2%$1.26B$45.57M-2.32600Upcoming EarningsHROWHarrow2.4981 of 5 stars$33.42+7.0%$63.83+91.0%+41.6%$1.23B$212.86M-59.68180Upcoming EarningsCVACCureVac4.4476 of 5 stars$5.46+0.9%$6.83+25.2%+58.3%$1.22B$523.70M5.93880Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PHVSPharvaris2.079 of 5 stars$21.24+6.2%$36.20+70.4%+31.3%$1.11BN/A-7.0630Positive NewsHigh Trading VolumePAHCPhibro Animal Health4.235 of 5 stars$27.14+3.9%$24.40-10.1%+53.0%$1.10B$1.02B34.801,940Positive NewsDividend AnnouncementAVDLAvadel Pharmaceuticals2.7003 of 5 stars$11.26+1.6%$18.33+62.8%-31.0%$1.09B$169.12M-41.7070Positive NewsUpcoming EarningsARDXArdelyx4.1305 of 5 stars$4.39+1.4%$10.88+147.7%-27.4%$1.05B$333.61M-19.9590News CoverageEarnings ReportPRAXPraxis Precision Medicines1.9021 of 5 stars$51.09-5.5%$94.11+84.2%-10.0%$1.04B$8.12M-4.77110Trending NewsEarnings ReportGap DownHigh Trading Volume Related Companies and Tools Related Companies Cidara Therapeutics Alternatives Intellia Therapeutics Alternatives Harrow Alternatives CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Pharvaris Alternatives Phibro Animal Health Alternatives Avadel Pharmaceuticals Alternatives Ardelyx Alternatives Praxis Precision Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
